Not so. Providing the patients in both arms were receiving the "maximal therapy" as specified by the trial protocol and the control arm patients received Remestemcel-L in addition, there doesn't seem to be a problem. The question being asked is, does adding Remestemcel-L improve mortality over the current standard of care in Covid ARDS?
The reasons given by SI for the trial failing might not stand up to much scientific scrutiny.
Novartis will be well equipped to decide since they will see the data. What they decide to do will be indicative.
Novartis deal on the rocks, page-81
-
- There are more pages in this discussion • 167 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |